Zonisamide 唑尼沙胺; AD 810; CI 912,99.94%

产品编号:Bellancom-B0124| CAS NO:68291-97-4| 分子式:C8H8N2O3S| 分子量:212.23

Zonisamide为1,2苯异恶唑衍生物,有抗癫痫活性。

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用,

货号 包装 价格 库存与货期 购买量 操作
Bellancom-B0124
860.00 杭州 北京(现货)
Bellancom-B0124
1360.00 杭州 北京(现货)

增值税发票√顺丰快递√订货电话:18601927057

Zonisamide 唑尼沙胺; AD 810; CI 912

产品介绍 Zonisamide (AD 810) 是一种口服有效的碳酸酐酶 (carbonic anhydrase) 抑制剂,对人类线粒体同工酶 hCA IIhCA VKi 值分别为 35.2 nM 和 20.6 nM。Zonisamide 可通过抗细胞凋亡和上调 MnSOD 水平来发挥神经保护作用。Zonisamide 还能增加 Hrd1 的表达,从而改善 AAC 大鼠的心脏功能。Zonisamide 可用于癫痫、帕金森和心脏肥大的研究。
生物活性

Zonisamide (AD 810) is an orally active carbonic anhydrase inhibitor, with Kis of 35.2 and 20.6 nM for hCA II and hCA V, respectively. Zonisamide exerts neuroprotective effects through anti-apoptosis and upregulating MnSOD levels. Zonisamide also increases the expression of Hrd1, thereby improving cardiac function in AAC rats. Zonisamide can be used in studies of seizure, parkinson’s disease and cardiac hypertrophy[4].

体外研究

Zonisamide (10, 50, 100, 200 µM; 24 h) increases viability of SH-SY5Y cells via an anti-apoptotic effect.
Zonisamide (100 µM; 24 h) shows neuroprotective effects in PD-cellular models. (PD: parkinson’s disease).
Zonisamide (100 µM; 24 h) reduces levels of proapoptotic molecules, and upregulates levels of MnSOD (MnSOD over-expression attenuates MPTP toxicity and protects cells from apoptosis).
Zonisamide (0.1, 0.3, 1 μM; 24 h) inhibits cardiac hypertrophy and fibrosis in vitro.
Zonisamide markedly increases the expression of Hrd1 in Ang II-treated NRCMs.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay

Cell Line: SH-SY5Y cells
Concentration: 10, 50, 100, 200 µM
Incubation Time: 24 h
Result: Induced an increase of cell viability, and with the greatest effect being at 100 µM.
Exhibited neuroprotective effect on SH-SY5Y cells (PD-cellular models) when at 100 µM.

Apoptosis Analysis

Cell Line: SH-SY5Y cells
Concentration: 100 µM
Incubation Time: 24 h
Result: Showed an effect of anti-apoptotic.

RT-PCR

Cell Line: NRCMs and cardiac fibroblasts (expose to Ang II for cardiomyocyte hypertrophy and fibrosis model)
Concentration: 0.1, 0.3, 1 μM
Incubation Time: 24 h
Result: Decreased the expression of atrial natriuretic factor (ANF) and cardiomyosin heavy chain β (β-MHC) but increased the expression of cardiac myosin heavy chain α (α-MHC) in NRCMs.
Decreased cardiac expression of the fibrosis-related gene Collagen 1A1 (Col1A1) in cardiac fibroblasts.

Western Blot Analysis

Cell Line: SH-SY5Y cells
Concentration: 100 µM
Incubation Time: 24 h
Result: Reduced the proapoptotic molecules levels of cleaved caspase-9, -3, and p-JNK, and blocked the activation of proapoptotic molecules in SH-SY5Y cells. Induced an increase in MnSOD levels.(MnSOD over-expression attenuates MPTP toxicity and protects cells from apoptosis).
体内研究
(In Vivo)

Zonisamide (40 mg/kg; i.p.; single daily for 14 days) prevents seizures in FeCl3-induced chronic amygdalar seizures model.
Zonisamide (14, 28, 56 mg/kg; i.p.; single daily for 6 weeks) alleviates cardiac hypertrophy and improved cardiac function in rats subjected to AAC (abdominal aortic constriction).
Zonisamide (14, 28, 56 mg/kg; i.p.; single daily for 6 weeks) upregulates Hrd1 expression and accelerates ERAD in the hearts of AAC rats.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Male Wistar rats (200-250 g; FeCl3-induced chronic amygdalar seizures).
Dosage: 40 mg/kg
Administration: Intraperitoneal injection; single daily for 14 days.
Result: Showed activity of anti-seizures.
Significantly down-regulated GABA transporters GAT-1 in the hippocampus.
Animal Model: Adult male Sprague-Dawley rats (100-120 g; cardiac hypertrophy model).
Dosage: 14, 28, 56 mg/kg
Administration: Intraperitoneal injection; single daily for 6 weeks.
Result: Significantly attenuated cardiac hypertrophy and fibrosis.
Increased LV ejection fraction (EF), fractional shortening (FS) and E/A ratio.
Markedly increased the expression of Hrd1 in the hearts of AAC rats.
体内研究

Zonisamide (40 mg/kg; i.p.; single daily for 14 days) prevents seizures in FeCl3-induced chronic amygdalar seizures model.
Zonisamide (14, 28, 56 mg/kg; i.p.; single daily for 6 weeks) alleviates cardiac hypertrophy and improved cardiac function in rats subjected to AAC (abdominal aortic constriction).
Zonisamide (14, 28, 56 mg/kg; i.p.; single daily for 6 weeks) upregulates Hrd1 expression and accelerates ERAD in the hearts of AAC rats.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Male Wistar rats (200-250 g; FeCl3-induced chronic amygdalar seizures).
Dosage: 40 mg/kg
Administration: Intraperitoneal injection; single daily for 14 days.
Result: Showed activity of anti-seizures.
Significantly down-regulated GABA transporters GAT-1 in the hippocampus.
Animal Model: Adult male Sprague-Dawley rats (100-120 g; cardiac hypertrophy model).
Dosage: 14, 28, 56 mg/kg
Administration: Intraperitoneal injection; single daily for 6 weeks.
Result: Significantly attenuated cardiac hypertrophy and fibrosis.
Increased LV ejection fraction (EF), fractional shortening (FS) and E/A ratio.
Markedly increased the expression of Hrd1 in the hearts of AAC rats.
体内研究

Zonisamide (40 mg/kg; i.p.; single daily for 14 days) prevents seizures in FeCl3-induced chronic amygdalar seizures model.
Zonisamide (14, 28, 56 mg/kg; i.p.; single daily for 6 weeks) alleviates cardiac hypertrophy and improved cardiac function in rats subjected to AAC (abdominal aortic constriction).
Zonisamide (14, 28, 56 mg/kg; i.p.; single daily for 6 weeks) upregulates Hrd1 expression and accelerates ERAD in the hearts of AAC rats.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Male Wistar rats (200-250 g; FeCl3-induced chronic amygdalar seizures).
Dosage: 40 mg/kg
Administration: Intraperitoneal injection; single daily for 14 days.
Result: Showed activity of anti-seizures.
Significantly down-regulated GABA transporters GAT-1 in the hippocampus.
Animal Model: Adult male Sprague-Dawley rats (100-120 g; cardiac hypertrophy model).
Dosage: 14, 28, 56 mg/kg
Administration: Intraperitoneal injection; single daily for 6 weeks.
Result: Significantly attenuated cardiac hypertrophy and fibrosis.
Increased LV ejection fraction (EF), fractional shortening (FS) and E/A ratio.
Markedly increased the expression of Hrd1 in the hearts of AAC rats.
性状Solid
溶解性数据
In Vitro: 

DMSO : 250 mg/mL (1177.97 mM; Need ultrasonic)

H2O : 0.67 mg/mL (3.16 mM; Need ultrasonic)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 4.7119 mL 23.5593 mL 47.1187 mL
5 mM 0.9424 mL 4.7119 mL 9.4237 mL
10 mM 0.4712 mL 2.3559 mL 4.7119 mL
*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂:

——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂: 10% DMSO    40% PEG300    5% Tween-80    45% saline

    Solubility: ≥ 2.08 mg/mL (9.80 mM); Clear solution

    此方案可获得 ≥ 2.08 mg/mL (9.80 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠,完全溶解于 100 mL ddH₂O 中,得到澄清透明的生理盐水溶液
  • 2.

    请依序添加每种溶剂: 10% DMSO    90% (20% SBE-β-CD in saline)

    Solubility: ≥ 2.08 mg/mL (9.80 mM); Clear solution

    此方案可获得 ≥ 2.08 mg/mL (9.80 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中,混合均匀。

    将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中,再用生理盐水定容至 10 mL,完全溶解,澄清透明
  • 3.

    请依序添加每种溶剂: 10% DMSO    90% corn oil

    Solubility: ≥ 2.08 mg/mL (9.80 mM); Clear solution

    此方案可获得 ≥ 2.08 mg/mL (9.80 mM,饱和度未知) 的澄清溶液,此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例,取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中,混合均匀。

  • 4.

    请依序添加每种溶剂: PBS

    Solubility: 1 mg/mL (4.71 mM); Clear solution; Need ultrasonic and warming and heat to 60°C

*以上所有助溶剂都可在 西域 网站选购。
运输条件

Room temperature in continental US; may vary elsewhere.

储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
参考文献

相关文档

化学品安全说明书(MSDS)

下载MSDS

质检证书(COA)

相关产品


符号 GHS02 GHS06 GHS08
GHS02, GHS06, GHS08
信号词 Danger
危害声明 H225-H301 + H311 + H331-H370
警示性声明 P210-P260-P280-P301 + P310-P311
危害码 (欧洲) Xn
风险声明 (欧洲) R22
安全声明 (欧洲) 7-16-36/37-45
危险品运输编码 UN1230 - class 3 - PG 2 - Methanol, solution
WGK德国 3
海关编码 2935009090
1. 物质的识别
产品名: Zonisamide
CAS号: 68291-97-4
制造商/供应商: 西域试剂
网站:www.hzbp.cn   邮件:13911702513@139.com
2. 合成/成分数据
产品名: Zonisamide
别名: CI-912
分子式: C8H8N2O3S
分子量: 212.23
3. 急救措施
吸入后: 如果吸入,移至空气新鲜处,如果呼吸困难,给输氧,如呼吸停止,给予人工呼吸。
皮肤接触后: 用大量的水冲洗,移除污染的衣服和鞋子。
眼睛接触后: 检查并取下隐形眼镜,并用大量的水冲洗;呼叫医生。
吞食后: 如果吞食,用大量纯净水漱口;呼叫医生。
4. 消防措施
适当的灭火剂: 雾状水,二氧化碳,干粉或泡沫。
防护设备: 穿戴自给式呼吸器和防护服,以防止与皮肤和眼睛接触。
5. 泄漏应急处理
安全防范措施: 封锁泄漏区域;穿戴自给式呼吸器,防护服和厚橡胶手套。
清洁/收集措施: 使用液体粘合原料(硅藻土,通用粘合剂)吸取精细粉末;
使用酒精擦洗表面和设备除去污渍;
根据第11条处理被污染的材料。
6. 处理和储存
安全处理说明: 避免吸入和接触皮肤,眼睛及衣物;材料可能略微具有刺激性。
储存: 粉末型式       -20°C   3年;4°C   2年
溶于溶剂       -80°C   6个月;-20°C   1个月
7. 接触控制和个人防护
呼吸设备: NIOSH / MSHA认可的呼吸器。
双手保护: 耐化学腐蚀的橡胶手套。
眼睛防护: 化学安全护目镜。
8. 稳定性和反应活性
稳定性: 按照说明存储是稳定的;避免强氧化剂。
热分解/其他要避免的情况: 避免光和热。
9. 毒性资料
急性毒性: 无可用资料。
主要刺激性影响: 无可用资料。
在皮肤上: 无可用资料。
对眼睛: 无可用资料;可能具有刺激性。
10. 生态资料
一般注意事项: 无可用资料。
11. 废弃处置
按照所在国家,省份,县市和地方的法规处置。
12. 运输信息
正确的运输名称:
非危险品运输: 这种物质被视为非危险品运输。
13. 法规信息
尚未有针对此产品作出的化学安全性评估。
14. 其他信息
这种化学品仅供受过训练的,有经验的研究人员在穿戴适当装备和授权允许的情况下进行操作处理。以上信息基于我们目前的知识被认为是正确的,但只适用于作为有经验人员的指导。请咨询您自己的安全顾问,并遵守当地和国家的安全法规。在任何其他没有被警告的情况下,并不意味着绝对没有危险存在。西域生物技术不承担任何使用这种化学品所造成的损害和责任。2023 西域生物技术版权所有。





~89%

68291-97-4结构式

68291-97-4

文献:WO2007/16208 A2, ; Page/Page column 16-17 ;

~75%

68291-97-4结构式

68291-97-4

文献:US2006/9644 A1, ; Page/Page column 10 ;

~86%

68291-97-4结构式

68291-97-4

文献:US2004/14983 A1, ; Page 4-5 ;

~%

68291-97-4结构式

68291-97-4

文献:US2007/66830 A1, ; Page/Page column 5 ;

服务热线

13911702513
18601927057

微信客服